Walleye Capital
TGTX icon

Walleye Capital’s TG Therapeutics TGTX Stock Holding History

Walleye Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
22,700
+8,400
+59% +$344K ﹤0.01% 1927
2026
Q1 		$475K Buy
14,300
+11,100
+347% +$331K ﹤0.01% 2713
2025
Q4 		$95.4K Sell
3,200
-24,800
-89% -$810K ﹤0.01% 3891
2025
Q3 		$1.01M Sell
28,000
-65,000
-70% -$2.14M ﹤0.01% 2085
2025
Q2 		$3.35M Buy
93,000
+15,800
+20% +$588K 0.01% 1132
2025
Q1 		$3.04M Buy
77,200
+53,300
+223% +$1.79M 0.01% 1125
2024
Q4 		$719K Sell
23,900
-6,200
-21% -$178K ﹤0.01% 2676
2024
Q3 		$704K Sell
30,100
-41,900
-58% -$915K ﹤0.01% 2982
2024
Q2 		$1.28M Buy
72,000
+43,300
+151% +$691K ﹤0.01% 2576
2024
Q1 		$437K Buy
28,700
+19,500
+212% +$311K ﹤0.01% 3316
2023
Q4 		$157K Sell
9,200
-32,900
-78% -$382K ﹤0.01% 3814
2023
Q3 		$352K Buy
42,100
+32,800
+353% +$457K ﹤0.01% 3098
2023
Q2 		$231K Sell
9,300
-3,900
-30% -$101K ﹤0.01% 2992
2023
Q1 		$199K Buy
+13,200
New +$201K ﹤0.01% 2479

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Walleye Capital's TGTX Position: Q2 2026 in Review

Walleye Capital increased its TG Therapeutics (TGTX) stake by 9,330% in Q2 2026, buying an estimated $7.71M and bringing the position to 190,302 shares worth $10.5M. The position accounts for 0.04% of the portfolio, ranked #459.

Walleye Capital first reported a position in TGTX in Q4 2019 and has held it in 14 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Walleye Capital held 190,302 shares of TG Therapeutics worth $10.5M as of Q2 2026.
  • Walleye Capital bought 188,284 TG Therapeutics shares in Q2 2026, an estimated $7.71M.
  • TG Therapeutics made up 0.04% of Walleye Capital's portfolio in Q2 2026, its #459 holding.
  • Walleye Capital first reported a position in TG Therapeutics in Q4 2019 and has held it in 14 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.